Astegolimab met its primary endpoint in the Phase IIb ALIENTO trial with a 15.4% reduction in annualized exacerbation rate at 52 weeks, while the Phase III ARNASA study showed a 14.5% reduction and ...

Topline data were announced from two phase 3 trials evaluating astegolimab in patients with moderate to very severe COPD.

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

One global clinical trial testing astegolimab for moderate to severe COPD hit its main goal, but another did not, Genentech ...

Roche AG’s Genentech unit disclosed outcomes of two studies testing IL-33-targeting astegolimab vs. placebo on top of standard-of-care maintenance therapy in subjects with moderate to very severe ...

Roche announced topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care ...

Roche gambled on an all-comer design for trials of its COPD candidate astegolimab, a move that may prove costly as it fails a phase 3 test.

Reckitt has named Karandeep Singh Duggal as new Region Head-Central India.Karandeep shared the news in a recent LinkedIn post ...